Aveanna Healthcare Holdings (AVAH) AI Stock Analysis

• Market Cap: $1.92B
• Dividend Yield: N/A
• Average Volume (3M): 1.59M
• Price to Earnings (P/E): 114.8
• Beta (1Y): 1.31
• Revenue Growth: 15.48%
• EPS Growth: N/A
• Country: US
• Employees: 33,500
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.15
• Shares Outstanding: 208,911,380
• 10 Day Avg. Volume: 1,446,371
• 30 Day Avg. Volume: 1,587,140
• PEG Ratio: 0.89
• Price to Book (P/B): -7.36
• Price to Sales (P/S): 0.44
• P/FCF Ratio: 34.15
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $10.19
• Price Target Upside: 16.46% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $9.50 ▲(8.57% Upside)

Aveanna Healthcare Holdings' overall score is primarily influenced by its strong earnings call performance, indicating robust revenue and EBITDA growth. However, financial performance is constrained by high leverage and negative equity, and valuation concerns arise from a high P/E ratio. Technical indicators show a positive trend, but valuation remains a significant risk.

Positive Factors

Revenue Growth

Strong revenue growth indicates Aveanna's expanding market presence and effective service delivery, enhancing its competitive position in the healthcare market.

EBITDA Performance

Significant EBITDA growth reflects improved operational efficiency and cost management, contributing to long-term profitability and financial health.

Strategic Initiatives

Expanding preferred payer agreements enhances revenue stability and strengthens partnerships, supporting sustainable growth in the healthcare services sector.

Negative Factors

High Leverage

High leverage and negative equity pose significant financial risks, potentially limiting Aveanna's ability to invest in growth and manage economic downturns.

Labor Market Challenges

Ongoing labor market challenges could impact service delivery and operational efficiency, affecting Aveanna's ability to scale and maintain quality care.

Regulatory Uncertainty

Regulatory and Medicaid funding uncertainties could affect reimbursement rates and financial planning, posing risks to Aveanna's revenue streams and profitability.

Aveanna Healthcare Holdings Business Overview & Revenue Model

Company Description

Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides private duty nursing (PDN), adult home health and hospice, home-based pediatric therapy, and enteral nutrition services in the United States. Its patient- centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers PDN services, which include in-home skilled nursing services to medically fragile children; nursing services in school settings in which its caregivers accompany patients to school; services to patients in its pediatric day healthcare centers; and employer of record support and personal care services, as well as in-clinic and home-based pediatric therapy services, such as physical, occupational, and speech services. The HHH segment provides home health services, including in-home skilled nursing services; physical, occupational, and speech therapy services; and medical social and aide services, as well as hospice services for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The MS segment offers enteral nutrition supplies and other products to adults and children delivered on a periodic or as-needed basis. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.

How the Company Makes Money

Aveanna Healthcare generates revenue primarily through the provision of home healthcare services billed to various payers, including private insurance, Medicaid, and Medicare. The company's revenue model is based on service contracts and reimbursement rates determined by these payers, which cover skilled nursing, therapy, and personal care services. Key revenue streams include hourly billing for nursing and therapy services, episodic payments for specific care episodes, and capitated payments for certain patient populations. Additionally, Aveanna's partnerships with healthcare providers and managed care organizations enhance their service offerings and can lead to increased patient referrals, further driving revenue growth. The company's focus on expanding its footprint in underserved markets and enhancing its service capabilities are also significant factors contributing to its earnings.

Aveanna Healthcare Holdings Financial Statement Overview

Summary

Aveanna Healthcare Holdings shows moderate revenue growth and improved cash flow generation. However, significant financial challenges exist due to high leverage and negative equity, impacting overall financial stability. Operational inefficiencies and low profitability margins further constrain financial performance.

Income Statement

Aveanna Healthcare Holdings shows moderate revenue growth with a TTM growth rate of 4.04%. Gross profit margin is stable at 33.2%, indicating efficient cost management. However, the net profit margin is low at 0.85%, suggesting challenges in translating revenue into profit. EBIT and EBITDA margins have improved but remain modest, reflecting operational inefficiencies.

Balance Sheet

The company has a concerning debt-to-equity ratio of -124.35, indicating high leverage and negative equity. This poses a significant financial risk. Return on equity is negative, reflecting poor profitability relative to shareholder investment. The equity ratio is also negative, highlighting financial instability.

Cash Flow

Free cash flow has grown significantly by 174.37% in the TTM, indicating improved cash generation. The operating cash flow to net income ratio is 0.21, suggesting moderate cash conversion efficiency. However, the high leverage and negative equity remain concerns for long-term cash flow sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2020	Dec 2019
Income Statement
Total Revenue	1.66B	2.02B	1.90B	1.79B	1.50B	1.38B
Gross Profit	551.44M	635.54M	595.43M	553.23M	454.51M	419.25M
EBITDA	159.80M	187.38M	44.35M	-517.28M	22.13M	44.28M
Net Income	-10.63M	-10.93M	-134.52M	-662.03M	-57.05M	-76.52M
Balance Sheet
Total Assets	1.77B	1.66B	1.61B	1.71B	1.84B	1.58B
Cash, Cash Equivalents and Short-Term Investments	100.74M	84.29M	43.94M	19.22M	137.34M	3.33M
Total Debt	1.49B	1.50B	1.50B	1.50B	1.23B	1.08B
Total Liabilities	1.78B	1.79B	1.74B	1.72B	1.58B	1.31B
Stockholders Equity	-11.26M	-122.09M	-127.44M	-4.17M	267.17M	270.94M
Cash Flow
Free Cash Flow	66.64M	26.32M	16.56M	-60.41M	101.38M	-25.35M
Operating Cash Flow	72.33M	32.64M	22.67M	-48.40M	116.62M	-8.71M
Investing Cash Flow	-20.54M	-6.32M	-8.79M	-25.29M	-193.54M	-17.82M
Financing Cash Flow	-4.54M	14.03M	10.85M	62.42M	210.94M	21.86M

Aveanna Healthcare Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 8.75
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVAH, the sentiment is Neutral. The current price of 8.75 is below the 20-day moving average (MA) of 9.47, below the 50-day MA of 8.86, and above the 200-day MA of 5.98, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 44.27 is Neutral, neither overbought nor oversold. The STOCH value of 35.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AVAH.

Aveanna Healthcare Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADUS	79 Outperform	$2.22B	24.44	8.58%	―	18.77%	6.88%
NHC	73 Outperform	$1.94B	18.63	10.65%	1.97%	25.19%	13.44%
PNTG	69 Neutral	$873.73M	32.33	10.87%	―	29.89%	10.33%
SEM	67 Neutral	$1.66B	15.35	5.57%	1.79%	-22.96%	-59.35%
BKD	60 Neutral	$2.20B	―	-108.91%	―	3.99%	-14.74%
AVAH	54 Neutral	$1.92B	114.76	―	―	15.48%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Aveanna Healthcare Holdings Corporate Events

Aveanna Healthcare Reports Strong Q3 2025 Financial Results

Aveanna Healthcare Holdings announced its third-quarter financial results for 2025, showing a significant improvement with a 22.2% increase in revenue to $621.9 million and a net income of $14.1 million compared to a net loss in the previous year. The company also revised its full-year 2025 revenue and Adjusted EBITDA guidance upwards, reflecting sustained business momentum and successful strategic transformations, including the integration of Thrive Skilled Pediatric Care.

The most recent analyst rating on (AVAH) stock is a Buy with a $12.50 price target. To see the full list of analyst forecasts on Aveanna Healthcare Holdings stock, see the AVAH Stock Forecast page.

Aveanna Healthcare Completes Secondary Stock Offering

On October 21, 2025, Aveanna Healthcare Holdings Inc. entered into an underwriting agreement for a secondary offering of 10,000,000 shares of common stock by certain selling stockholders affiliated with J.H. Whitney Equity Partners VII, LLC. The offering, which closed on October 23, 2025, was priced at $9.00 per share, with an option for underwriters to purchase an additional 1,500,000 shares. The company did not issue or sell any shares itself and did not receive any proceeds from this transaction.

The most recent analyst rating on (AVAH) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Aveanna Healthcare Holdings stock, see the AVAH Stock Forecast page.

Aveanna Healthcare Highlights Transparency in Investor Presentation

On September 29, 2025, Aveanna Healthcare Holdings Inc. released a financial presentation to investors, highlighting the company’s use of its website to disseminate important information. The presentation, which is available on their website, underscores Aveanna’s commitment to transparency and timely communication with stakeholders, potentially impacting investor relations and market perception.

The most recent analyst rating on (AVAH) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Aveanna Healthcare Holdings stock, see the AVAH Stock Forecast page.

Aveanna Healthcare Refinances Credit Facility for Growth

On September 17, 2025, Aveanna Healthcare Holdings successfully refinanced its first lien credit facility, increasing its revolving credit facility to $250 million and extending the maturity dates of its loans. This refinancing allowed Aveanna to repay its existing second lien term loans, thereby terminating the second lien term loan facility. The move strengthens Aveanna’s balance sheet, enhances liquidity, and reflects strong operational performance and confidence from financial partners, supporting the company’s strategic growth and expansion.

The most recent analyst rating on (AVAH) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Aveanna Healthcare Holdings stock, see the AVAH Stock Forecast page.

Aveanna Healthcare’s Earnings Call Highlights Growth and Optimism

Aveanna Healthcare Holdings Inc. recently held its earnings call, revealing a positive sentiment driven by strong revenue and EBITDA growth. The company has achieved significant milestones through strategic transformations, preferred payer agreements, and successful integration of acquisitions. However, challenges persist in the labor market, regulatory headwinds in home health, and potential Medicaid funding concerns. Despite these hurdles, the overall outlook remains optimistic due to the company’s achievements and growth prospects.

Aveanna Healthcare Highlights Strong Financial Performance

On August 8, 2025, Aveanna Healthcare Holdings Inc. released a financial presentation to investors, highlighting key operating statistics and financial metrics. The presentation reported over $2.3 billion in revenue, a gross margin of 34.3%, and an adjusted EBITDA exceeding $270 million. The company operates 366 locations with 29,000 caregivers, delivering 43.9 million homecare hours annually. This announcement underscores Aveanna’s robust operational scale and financial performance, reinforcing its position as a major player in the home healthcare sector.

The most recent analyst rating on (AVAH) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Aveanna Healthcare Holdings stock, see the AVAH Stock Forecast page.

Aveanna Healthcare Reports Strong Q2 Growth and Raises 2025 Outlook

Aveanna Healthcare Holdings Inc. is a leading home care platform providing services to medically complex, high-cost patient populations across the United States. The company operates in the healthcare sector, focusing on delivering care in the comfort of patients’ homes, which offers a cost-effective alternative to prolonged hospitalization.

Aveanna Healthcare Reports Strong Q2 2025 Financial Growth

Aveanna Healthcare Holdings announced its second-quarter financial results for 2025, showing significant growth in revenue and adjusted EBITDA compared to the previous year. The company reported a 16.8% increase in revenue to $589.6 million and a 93.6% increase in adjusted EBITDA to $88.4 million. The acquisition of Thrive Skilled Pediatric Care has expanded Aveanna’s pediatric services, contributing to its strategic transformation and market expansion. The company has raised its full-year 2025 revenue guidance to over $2.3 billion and adjusted EBITDA to over $270 million, reflecting strong operational performance and growth momentum.

The most recent analyst rating on (AVAH) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Aveanna Healthcare Holdings stock, see the AVAH Stock Forecast page.